List of Verkazia drug patents
Verkazia is owned by Santen.
Verkazia contains Cyclosporine.
Verkazia has a total of 6 drug patents out of which 0 drug patents have expired.
Verkazia was authorised for market use on 23 June, 2021.
Verkazia is available in emulsion;ophthalmic dosage forms.
The generics of Verkazia are possible to be released after 02 June, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9220694 | SANTEN | Emulsion compositions containing cetalkonium chloride |
Jan, 2026
(2 years from now) | |
| US7973081 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
| US8524779 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
| US9956289 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
| US8298568 | SANTEN | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Nov, 2027
(4 years from now) | |
| US9132071 | SANTEN | Compositions containing quaternary ammonium compounds |
Jun, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 23, 2028 |
| New Product (NP) | Jun 23, 2024 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
VERKAZIA family patents
15
European Union
14
United States
8
Spain
7
Japan
6
Denmark
6
Austria
6
Germany
6
Portugal
5
Israel
5
Korea, Republic of
5
China
4
Australia
4
Hong Kong
4
Poland
4
Canada
3
Slovenia
3
Hungary
3
Cyprus
2
Mexico
2
Lithuania
1
South Africa
1
IB
1
Luxembourg
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic